How 503A Compounding Pharmacies Can Partner with Telehealth Prescribers — Compliantly

Demand for compounded GLP-1 therapies, hormone formulations, and personalized wellness medications has surged alongside the telehealth boom. 503A compounding pharmacies that want to serve this market have a real opportunity — but the legal guardrails are sharp. One mis-structured partnership can constitute a federal Anti-Kickback violation. This guide maps the compliant path from introduction through ongoing operations.

Why the 503A–Telehealth Intersection Is High-Value and High-Risk

Section 503A of the Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound patient-specific medications based on valid prescriptions. Telehealth platforms have become a dominant prescription origination channel: a patient sees a clinician via video or asynchronous intake, receives a prescription for a compounded semaglutide, testosterone, or NAD+ formulation, and the compound ships directly to their door.

The business logic is obvious. The legal exposure is equally obvious. Pharmacies that pay telehealth platforms for "exclusive preferred pharmacy" status, or that structure per-prescription revenue-share arrangements, are walking into Anti-Kickback Statute (AKS) territory — a federal criminal statute with no ceiling on fines and no statute-of-limitations comfort zone. The same arrangements may also implicate state pharmacy referral laws, fee-splitting statutes, and corporate practice of medicine (CPOM) doctrines depending on how they are structured.

Getting this right matters not just for legal protection, but for the credibility of the entire compounding industry at a moment when FDA scrutiny is already elevated.

The Non-Negotiable Legal Framework

Anti-Kickback Statute: What It Actually Prohibits

42 U.S.C. § 1320a-7b(b) prohibits knowingly and willfully offering, paying, soliciting, or receiving anything of value to induce or reward referrals of items or services covered by a federal healthcare program. Even if a transaction is structured as a "marketing fee" or "technology fee," courts and the OIG look at substance over form. If the fee correlates with prescription volume — even implicitly — it is a red flag.

The safe side of the line: A compounding pharmacy may pay a flat monthly fee to a telehealth technology provider for documented services (e-prescribing integration, patient education portal, formulary data feed) where the fee is set at fair market value (FMV), is not tied to prescription volume, and reflects a genuine service that would exist regardless of whether any particular patient fills at that pharmacy.

The illegal side of the line: A per-prescription payment, a percentage-of-revenue arrangement, a "preferred pharmacy" placement fee, a discount on pharmacy services contingent on referral volume, or any structure where more prescriptions directed to the pharmacy means more money for the telehealth platform or its employed or affiliated prescribers.

"The moment a pharmacy's payment to a platform goes up when prescriptions go up, you have a per-referral fee by another name — and the AKS does not care what you call it." — Common framing in OIG advisory opinion requests

The Good-Faith Exam Requirement

A 503A pharmacy may only dispense pursuant to a valid prescription. A prescription is valid only when the prescriber has established a legitimate patient–prescriber relationship, which requires a clinically sufficient Good-Faith Exam (GFE). For telehealth prescribers, this means the prescriber reviewed a complete health history, evaluated the patient's suitability for the requested compound, and documented independent clinical judgment — not just rubber-stamped an intake form.

Pharmacy liability here is real: if a pharmacy knowingly dispenses pursuant to prescriptions that were issued without a valid GFE (e.g., from a platform operating a "prescription mill"), the pharmacy can face Board of Pharmacy discipline, DEA action, and in severe cases, criminal exposure. Vet your prescriber relationships. Ask for GFE documentation policies before you agree to receive prescriptions from any telehealth network.

MDside's review portal provides structured GFE workflows with tamper-evident audit logs that pharmacies can reference when evaluating prescriber partners.

Patient Freedom of Pharmacy Choice

Federal law (42 U.S.C. § 1395w-4) and most state pharmacy practice acts protect a patient's right to choose their pharmacy. No partnership agreement between a telehealth network and a compounding pharmacy may restrict this right, steer patients away from other pharmacies through financial incentives, or penalize a patient for exercising it. The prescriber must communicate this right to the patient at the point of prescribing. Document it.

What a Compliant Partnership Structure Looks Like

Step 1: Identify Legitimate Service Relationships

Before any contract is signed, map the actual services each party will perform. Legitimate pharmacy-to-platform service relationships typically include:

• E-prescribing integration: The pharmacy connects its dispensing system to the platform's EHR or intake tool. Fair-market-value technology integration fees are defensible.
• Formulary and pricing transparency: The pharmacy provides up-to-date compound formularies, pricing, and turnaround-time data that clinicians can reference — but not as an exclusive directory that steers patients.
• Pharmacist consultation services: The pharmacy provides dedicated pharmacist access for clinical questions, prior authorization support, or patient adherence calls. This is a real service with real FMV.
• Patient education materials: Co-developed, pharmacy-brand-neutral educational content about compound medications, storage, and administration. FMV: typically modest flat fee or per-piece rate, not per-script.
• De-identified outcome data: Aggregate, de-identified dispensing or refill data useful for quality improvement. HIPAA-compliant data sharing agreements are required.

Step 2: Set Pricing at FMV — and Document It

FMV is not a number you set arbitrarily. It requires a contemporaneous, documented analysis: What would an arm's-length buyer pay for this specific service from an unaffiliated vendor? Use benchmarking data, hourly rate surveys for pharmacists, and technology vendor comparisons. Document this analysis before the contract is signed. The OIG has been clear that FMV must be established in advance, not back-calculated to justify a pre-agreed payment.

Step 3: Decouple Fee Triggers from Prescription Volume

The contract should specify a flat monthly or annual fee for each defined service, with no escalators tied to prescription count, revenue generated, or number of patients enrolled. If the pharmacy wants usage-based pricing for, say, e-prescribing transaction volume, it should reflect actual technology costs — not a disguised per-script payment. Have healthcare counsel review the escalator provisions specifically.

Step 4: Verify Prescriber Independence

The telehealth platform's prescribers must exercise independent clinical judgment on every prescription. The pharmacy should confirm, in writing, that the platform does not direct prescribers toward specific compound formulations based on pharmacy financial relationships. Prescribers should be contractually prohibited from receiving any financial benefit tied to pharmacy selection. If the telehealth platform employs prescribers who are also shareholders in the pharmacy, CPOM violations and additional AKS risk arise — seek separate counsel immediately.

State Law Variation: Where Additional Rules Apply

503A is federal, but pharmacy practice is state-regulated. Key state-level considerations:

• Telehealth prescribing standards: Texas, Arkansas, and several other states require a synchronous audio-video encounter before prescribing compounded medications in certain categories. Asynchronous questionnaire-only intake is insufficient in these states. Confirm prescribing-modality requirements state by state.
• State fee-splitting statutes: Many states prohibit splitting professional fees between licensed and unlicensed entities. A pharmacy paying a non-licensed technology company is generally fine; a pharmacy paying a percentage of revenue to an entity that employed or managed prescribers is not.
• State AKS analogs: California (Bus. & Prof. Code § 650), Florida (§ 456.054), and others have state anti-kickback laws that apply to non-federal-program patients. Your compliance analysis must cover both federal and state exposure.
• Pharmacy licensure in ship-to states: A 503A pharmacy must be licensed in every state where it ships. Confirm non-resident pharmacy licensure is current before accepting prescriptions from a telehealth platform serving multi-state patients.

State law changes frequently. The analysis that cleared compliance counsel in 2023 may not reflect 2026 rules. Build in an annual legal review cadence.

Operationalizing Compliance: What to Build

Written Policies and SOPs

Document every element of the partnership in written standard operating procedures: how prescriptions are received, how GFE adequacy is assessed, how patient pharmacy choice is communicated, and how complaints are handled. The presence of documented, implemented policies is a key mitigating factor in any regulatory inquiry.

GFE Verification Protocol

Establish a protocol for pharmacy staff to flag and hold prescriptions where GFE documentation appears inadequate — missing required fields, implausibly short consultation times, or bulk prescription patterns inconsistent with individualized patient care. This is not second-guessing the prescriber's clinical judgment; it is the pharmacy fulfilling its own professional responsibility.

Audit Trails and Contract Documentation

Retain all FMV documentation, service agreements, invoices, and correspondence with prescriber partners for at least seven years. If the pharmacy is ever audited by a state board or investigated by the OIG, a clean paper trail demonstrating that fees were flat, services were real, and prescriber independence was protected is your primary defense.

How MDside Fits into a Compliant Partnership

MDside provides the licensed medical layer — physician-owned medical practice infrastructure, GFE-workflow technology, and prescriber networks — operating under a PC-MSO structure that preserves prescriber independence and CPOM compliance. Pharmacies that partner with telehealth networks powered by MDside's infrastructure benefit from built-in GFE audit logs, structured prescription origination workflows, and per-clinic IntakeQ key isolation that keeps patient data properly compartmentalized.

MDside charges flat, fair-market-value technology and administrative service fees. No per-prescription fees. No revenue share. No preferred-pharmacy steering. If you are a 503A pharmacy evaluating telehealth prescriber relationships and want to understand how a compliant infrastructure partner operates, book a discovery call or review our prescriber network overview.

Pharmacies looking to expand into the medical weight loss space may also want to read our companion article on adding medical weight loss to a gym or fitness facility — a common referral source for GLP-1 and metabolic compounds.